NCT05731895View on ClinicalTrials.gov

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

December 11, 2023

Study Completion Date

December 11, 2023

Conditions
Hepatic Insufficiency
Interventions
DRUG

BI 425809 (iclepertin)

BI 425809 (iclepertin)

Trial Locations (1)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY